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Abstract
Background. Renal calcium stones and hypercalciuria are
associated with a reduced bone mineral density (BMD).
Therefore, the effect of changes in calcium homeostasis
is of interest for both stones and bones. We hypothesized
that the response of calciuria, parathyroid hormone (PTH)
and 1.25 vitamin D to changes in dietary calcium might be
related to BMD.
Methods. A single-centre prospective interventional study
of 94 hyper- and non-hypercalciuric calcium stone formers
consecutively retrieved from our stone clinic. The patients
were investigated on a free-choice diet, a low-calcium diet,
while fasting and after an oral calcium load. Patient groups
were defined according to lumbar BMD (z-score) obtained
by dual X-ray absorptiometry (group 1: z-score <−0.5, n
= 30; group 2: z-score −0.5–0.5, n = 36; group 3: z-score
>0.5, n = 28). The effect of the dietary interventions on
calciuria, 1.25 vitamin D and PTH in relation to BMD was
measured.
Results. An inverse relationship between BMD and calci-
uria was observed on all four calcium intakes (P = 0.009).
On a free-choice diet, 1.25 vitamin D and PTH levels were
identical in the three patient groups. However, the relative
responses of 1.25 vitamin D and PTH to the low-calcium
diet were opposite in the three groups with the highest in-
crease of 1.25 vitamin D in group 1 and the lowest in group
3, whereas PTH increase was most pronounced in group 3
and least in group 1.
Conclusion. Calcium stone formers with a low lumbar
BMD exhibit a blunted response of PTH release and an
apparently overshooting production of 1.25 vitamin D fol-
lowing a low-calcium diet.
Keywords: 1.25 vitamin D; bone mineral density;
hypercalciuria; nephrolithiasis; parathyroid hormone
Correspondence and offprint requests to: Andreas Pasch, Depart-
ment of Nephrology and Hypertension, Inselspital, University of
Bern, Freiburgstrasse 10, CH-3010 Bern, Switzerland. E-mail: andreas.
pasch@insel.ch
Introduction
In the western world, renal calcium stone disease has a life-
time prevalence of about 10% [1]. Over the last 30 years,
epidemiological evidence associating renal calcium stone
disease and decreased bone mineral density (BMD) has
accumulated [2–6]. By using single photon absorptiometry
[6,7], quantitative computed tomography [2,8], dual photon
absorptiometry [3] and dual energy X-ray absorptiometry
[4,5], a diminished BMD was found at the lumbar spine
[2,3,8], radius [4,6,7] and tibia [5] in calcium stone formers.
The clinical relevance of this association was underlined by
large retrospective cohort studies showing an increased risk
of vertebral fractures in calcium stone formers [9,10]. Fur-
thermore, the decreased BMD in calcium stone formers was
linked to hypercalciuria in most [2–4,7,8], but not all [5],
studies. Calciuria is a continuous trait and is the final result
of numerous regulatory processes, including intestinal cal-
cium absorption, bone resorption and renal reabsorption.
Defining hypercalciuria is difficult and attempts by Pak
et al. are often used as a reference [11–13]. These protocols
allow us to subclassify hypercalciuria according to calcium
excretion during the intake of different amounts of cal-
cium. In short, idiopathic hypercalciuria is defined either
as fasting (also called dietary independent and including
renal calcium leak) when occurring under a low-calcium
diet, or as absorptive (also called dietary dependent) when
occurring after an oral calcium load. Using this defini-
tion, fasting [3,8] as well as absorptive hypercalciuria [2,4]
has been found to be associated with a diminished BMD in
some studies. Higher 1.25 vitamin D plasma concentrations
and lower PTH levels were encountered under free-choice
diet conditions in patients diagnosed with absorptive and
fasting hypercalciuria when compared to normocalciuric
stone formers [2,4,8,14]. In line with these reports, an ele-
vated production rate of 1.25 vitamin D has been reported
in absorptive hypercalciuria [15,16].
In contrast to the numerous reports on hypercalciuria and
its association with diminished BMD, reports that study the
BMD and the urinary calcium excretion of stone formers
with regard to the regulation of mineral metabolism under
different calcium intakes are rare. Bataille et al. [2] found
a positive correlation between 1.25 vitamin D and BMD
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when measured in a subgroup of 24 calcium stone formers
with dietary-independent hypercalciuria under fasting con-
ditions. However, no data on PTH levels were reported in
this study.
We hypothesize now that PTH and 1.25 vitaminD change
differently when calcium stone formers with high, inter-
mediate and low BMD are challenged for diagnostic pur-
poses by a low-calcium diet for 1 week. As the reference
site for the analysis of BMD we chose the lumbar spine
that is the only skeletal site exhibiting a higher fracture
rate in stone formers when compared to non-stone form-
ers [9,10]. The present investigation revealed that when
all calcium stone formers were considered as one group,
a low-calcium diet decreased calcaemia and calciuria, and
increased PTH and 1.25 vitamin D levels. However, when
the patients were grouped according to their BMD, a differ-
ential BMD-dependent response of PTH and 1.25 vitamin
D to the low calcium diet was observed.
Methods
Patient data
All patients were seen for an outpatient metabolic work-
up at our renal stone clinic between March 2004 and June
2006 and were included into the study independently of
their degree of calciuria. Inclusion criteria were as follows:
(i) ≥18 years of age of either gender and (ii) passage of at
least one calcium-containing kidney stone, defined either
by stone analysis or by the presence of opaque material on
conventional radiograph or computed tomography in the ab-
sence of cystinuria. Exclusion criteria were (i) established
cause of calcium stone formation, such as primary hyper-
parathyroidism, overt distal renal tubular acidosis, sarcoido-
sis, excessive vitamin D intake, hypercalciuria due to hy-
percalcaemia (immobilization or malignancy) and primary
or enteric hyperoxaluria (exclusion of patients with inflam-
matory bowel disease and short bowel syndrome); (ii) cre-
atinine clearance>60 ml/min as calculated from the serum
and urinary creatinine of two 24-h urine collections and (iii)
urinary tract infection. Patients were asked to stop calcium
supplements or any drug that could affect themetabolism of
calcium during the evaluation. All patients gave their con-
sent for their participation and the protocol was approved
by the institutional review board of the University Hospital
Bern.
Ninety-four patients met the above-mentioned criteria.
The results of the first 30 patients recruited had been pre-
sented at the 38th American Society of Nephrology An-
nual Renal Week Meeting 2005 at Philadelphia (Abstract
554925). The results derived from these 30 patients were
similar to those of the 64 subjects recruited thereafter.
Therefore, the results of all 94 patients were pooled.
Ambulatory protocol
All patients underwent a three-visit mineral metabolism
work-up including an osteodensitometry. A routine clinical
assessment including a physical examination and history
was performed. Mineral metabolism was investigated on
four different calcium regimens according to a protocol
first established by Pak et al. [11]: (i) free-choice diet,
(ii) low-calcium diet, (iii) fasting and (iv) after a 1 g oral
calcium load (Figure 1).
(i) While on their normal free-choice diet, patients led a
5-day dietary diary [13], collected 24-urines twice, and
had a blood sample drawn.
(ii) The dietary diaries were analysed by a nutritionist for
meat and calcium intake. Then patients were instructed
to follow a diet restricted in calcium (10 mmol or
400 mg/day) and sodium (100 mmol/day) under am-
bulatory conditions for 7 days. On the last day, a 24-
h urine collection was obtained which partially over-
lapped with a 12-h overnight fasting period.
(iii) The next day, the second ambulatory visit took place in
our clinic. Bloodwas drawn and 2-h urinewas collected
under fasting conditions.
(iv) After completion of this collection, patients received
1 g of calcium orally (Calcium Sandoz ff R©, containing
calcium carbonate, lactate and gluconate in 300 ml
distilled water). After this calcium load, a 4-h urine
collection was performed.
In the 24-h urines, volume, sodium, phosphate, calcium,
magnesium, creatinine, uric acid and ureaweremeasured by
standard laboratory techniques with an automated analyser.
Sulfate and oxalate were measured by high performance
liquid chromatography (Dionex DX-600 analyser). De-
oxypyridinoline was measured by an immunoassay (DPC,
Immunolite 2500) in the urine samples obtained during
the free-choice diet. In the 2- and 4-h urines, volume, cal-
cium and creatinine were assessed by standard laboratory
methods. In the blood samples sodium, phosphate, calcium,
uric acid and creatinine were assessed by standard labora-
tory methods. Intact parathyroid hormone was measured by
an enzyme-immunoassay (Roche Modular E170), and 1.25
Fig. 1. Schematic illustration of the protocol. Distances are not drawn to scale.
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vitamin D was also measured by an enzyme-immunoassay
(Immundiagnostik AG). Blood for themeasurement of total
alkaline phosphatase was taken while the subjects were on
the free-choice diet and was measured by standard labora-
tory methods.
Hypercalciuria was defined as either fasting or absorp-
tive hypercalciuria. Fasting hypercalciuria was defined as
an elevated fasting urinary calcium [≥0.00275 mmol/dl
glomerular filtrate (dl GF) or ≥0.11, mg/dl GF] in the 2-h
urine sample as described by Levy et al. [13]. Absorp-
tive hypercalciuria was defined as a urinary calcium-to-
creatinine ratio of ≥0.56 mmol/mmol (≥0.20, mg/mg) in
the 4-h urine sample after the oral intake of 1-g calcium
[13]. Osteodensitometry was performed by dual-energy
X-ray absorptiometry at the second to fourth lumbar ver-
tebra, femoral neck and tibial dia- and epiphysis (DXA,
Hologic R© scanner QDR 1000W).
Statistical analysis
Results are expressed asmean± SEM. Comparisons within
groups (between diets) were carried out by Student’s t-test
for paired observations. The chi-square likelihood ratio
test was used to compare the number of normo- and hy-
percalciuric patients within the groups. ANOVA, followed
by the Student–Newman–Keuls t-test for comparison of
means (post hoc analysis) was used for comparison between
groups. Reported P-values (two-tailed) of ≤0.05 were con-
sidered significant.
Results
Effects of a low-calcium diet
Urine and plasma values of 94 calcium stone-forming pa-
tients were investigated. The number of female and male
patients in our study (18 versus 76) reflects the gender
difference of stone-forming propensity reported in the lit-
erature [1]. Analyses were performed on four different di-
etary calcium intakes (Figure 1) including their usual free-
choice diet and after 1 week of a diet low in calcium and
sodium content—for simplicity termed ‘low-calcium diet’
hereafter. Figure 2 shows the impact of these two diets on
relevant variables of mineral metabolism. The low-calcium
diet caused a significant decline of plasma calcium, plasma
phosphate levels, the fractional excretion of phosphate and
urinary calcium excretion. Furthermore it caused an in-
crease of the 1.25 vitamin D and PTH concentrations.
Bone mineral density as a grouping variable
Patients were divided into three subgroups according to
their z-score at the lumbar spine (group 1: z-score <
−0.5; group 2: z-score −0.5–0.5; group 3: z-score >0.5)
(Table 1). There were 30 patients (5 females, 25 males)
in group 1, 36 (6 females, 30 males) in group 2 and 28
(7 females, 21 males) in group 3. Of the five post-
menopausal women included in this study, four belonged
to group 2 and one to group 3. No significant differences
Fig. 2. Effect of free-choice (Fc) and low-calcium diet (Lc) on plasma
concentrations of calcium, phosphate, 1.25 vitamin D, parathyroid hor-
mone (PTH), calciuria and fractional excretion (FE) of phosphate in all
patients investigated (n = 94). Error bars indicate SEM.
between groups were detected regarding age, body height,
weight, body mass index, family history of stones, stone re-
currences and the number of stone events per patient. Upon
evaluation of the 5-day dietary diaries, there was a slight but
non-significantly higher calcium and meat intake in group
2 when compared to group 1.
Plasma and urine values on free-choice diet and after 1
week of low-calcium diet are given in Tables 2 and 3. On
free-choice diet no significant difference between the three
groups in any plasma or urine parameter was detected.
Plasma and urinary sodium and calcium, as well as uri-
nary phosphate, uniformly declined in all groups while on
a low-calcium diet. Plasma phosphate declined in groups 2
and 3 but not group 1 on the low-calcium diet (Tables 2 and
3). Plasma uric acid levels homogenously increased in all
groups (Table 2), without a change in uric acid excretion
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Table 1. Baseline characteristics of patients grouped according to their z-scores at lumbar spine
All (n = 94) Group 1 z-score <−0.5
(n = 30)
Group 2 z-score
−0.5–0.5 (n = 36)
Group 3 z-score >0.5
(n = 28)
Female/male 18/76 5/25 6/30 7/21
Age (years) 46.3 ± 1.3 45.1 ± 2.3 46.6 ± 2.2 47.1 ± 2.1
Body height (cm) 173.6 ± 0.9 173.0 ± 1.3 173.0 ± 1.3 174.5 ± 2.0
Body weight (kg) 77.2 ± 1.6 74.7 ± 2.8 78.8 ± 2.4 78.0 ± 3.1
BMI (kg/m2) 25.5 ± 0.4 24.8 ± 0.8 26.2 ± 0.7 25.5 ± 0.8
Osteodensitometry
z-score lumbar spine 0.04 ± 0.10 −0.92 ± 0.07 −0.08 ± 0.04 1.21 ± 0.13
t-score lumbar spine −0.50 ± 0.10 −1.40 ± 010 −0.66 ± 0.08 0.66 ± 0.14
Normocalciuria 67 16 28 23
Fasting hypercalciuria 9 5 2 2
Absorptive hypercalciuria 18 9 6 3
Stone composition
Calcium oxalate 44 15 17 12
Calcium phosphate 4 1 2 1
Radio-opaque concrement 46 14 17 15
Stone recurrence, % of patients 86 80 92 86
Number of stone events per patient 2.9 ± 0.1 2.8 ± 0.2 3.3 ± 0.2 2.7 ± 0.2
Family history of stones, % of patients 35 40 33 32
Dietary diary on free-choice diet
Calcium intake (g/day) 809 ± 42 760 ± 64 906 ± 74 747 ± 76
Meat intake (g/kg/day) 1.69 ± 0.10 1.45 ± 0.14 1.88 ± 0.17 1.72 ± 0.19
Table 2. Comparison of plasma parameters on free-choice (Fc) and low-calcium (Lc) diet
Diet All patients
(n = 94)
Group 1 z-score
<−0.5 (n = 30)
Group 2 z-score
−0.5–0.5 (n = 36)
Group 3 z-score
>0.5 (n = 28)
ANOVA group 1
versus 2 versus 3
Creatinine (µmol/1) (45–04) Free-choice 78 ± 2 75 ± 2 77 ± 3 83 ± 4 0.11
Low calcium 81 ± 2 78 ± 2 80 ± 2 86 ± 4 0.15
P (Fc versus Lc) <0.001 0.02 0.004 0.18
Sodium (mmol/l) (132–142) Free-choice 142 ± 0.2 141 ± 0.3 142 ± 0.3 142 ± 0.4 0.19
Low calcium 139 ± 0.2 139 ± 0.3 139 ± 0.4 140 ± 0.4 0.46
P (Fc versus Lc) <0.001 <0.001 <0.001 <0.001
Calcium (mmol/l) (1.13–1.30) Free-choice 1.23 ± 0.00 1.23 ± 0.00 1.23 ± 0.01 1.23 ± 0.00 0.57
Low calcium 1.20 ± 0.00 1.20 ± 0.01 1.21 ± 0.01 1.19 ± 0.01 0.16
P (Fc versus Lc) <0.001 <0.001 0.002 <0.001
Phosphate (mmol/l) (0.74–1.55) Free-choice 1.06 ± 0.02 1.01. ± 0.03 1.08 ± 0.03 1.09 ± 0.03 0.10
Low calcium 0.98 ± 0.02 0.97 ± 0.03 0.98 ± 0.03 0.99 ± 0.03 0.80
P (Fc versus Lc) <0.001 0.12 0.002 <0.001
Uric acid (µmol/l) (140–340) Free-choice 307 ± 9 306 ± 15 309 ± 16 305 ± 16 0.98
Low calcium 354 ± 11 347 ± 16 364 ± 16 350 ± 25 0.79
P (Fc versus Lc) <0.001 <0.001 <0.001 0.05
PTH (pg/ml) (10–73) Free-choice 43.0 ± 1.3 43.1 ± 2.2 43.2 ± 2.1 42.8 ± 2.7 0.99
Low calcium 47.1 ± 1.5 44.7 ± 2.4 46.6 ± 2.3 50.3 ± 3.0 0.31
P (Fc versus Lc) 0.007 0.55 0.13 0.01
1.25 vitamin D (pmol/l) (78–160) Free-choice 120 ± 5.0 127 ± 9.8 113 ± 7.9 121 ± 8.1 0.52
Low calcium 153 ± 5.3 166 ± 9.8 158 ± 8.2 135 ± 9.3 0.07
P (Fc versus Lc) <0.001 <0.001 <0.001 0.13
Alkaline phosphatase, (U/l) (36–120) Free-choice 65.0 ± 1.8 65.1 ± 2.9 64.2 ± 2.9 65.8 ± 3.4 0.93
The numbers in parentheses indicate the normal range of values.
(Table 3). Alkaline phosphatase activity was comparable
between the three groups (Table 2). Creatinine clearance de-
creased slightly in all groups, but significance was reached
in group 3 only (Table 3). No differences among groups
were found for plasma venous pH and bicarbonate, and uri-
nary volume, creatinine, urea, sulfate, oxalate, citrate and
deoxypyridinoline/creatinine ratio (data not shown).
In Figure 3 the relationship between 1.25 vitamin D and
PTH in the three patient groups is given. On free-choice
diet, no statistically significant differences between the
three groups were found (Table 2). On the low-calcium diet,
however, a BMD-dependent disparitywas encountered. The
1.25 vitamin D concentration increased mainly in groups 1
and 2, whereas PTH increased mainly in group 3 (Figure
3, ANOVA P = 0.03 for the difference of the 1.25 vitamin
D-to-PTH ratios on low-calcium diet, post hoc analysis P
< 0.05 for group 1 versus group 3). No gender difference
was encountered for this ratio (ANOVA P = 0.76).
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Table 3. Comparison of 24-h urine parameters on free-choice (Fc) and low-calcium (Lc) diet
Diet All patients
(n = 94)
Group 1 z-score
<−0.5 (n = 30)
Group 2 z-score
−0.5–0.5 (n = 36)
Group 3 z-score
>0.5 (n = 28)
ANOVA group 1
versus 2 versus 3
Creatinine clearance (ml/min) (75–142) Free-choice 123 ± 3 130 ± 6 122 ± 4 117 ± 7 0.31
Low calcium 117 ± 4 126 ± 8 117 ± 5 107 ± 5 0.13
P (Fc versus Lc) 0.02 0.48 0.24 0.02
Sodium (mmol/day) (127–287) Free-choice 194 ± 7 195 ± 14 190 ± 11 197 ± 11 0.91
Low calcium 96 ± 5 101 ± 9 93 ± 8 94 ± 6 0.73
P (Fc versus Lc) <0.001 <0.001 <0.001 <0.001
Calcium (mmol/day) (2.5–7.5) Free-choice 6.85 ± 0.34 7.26 ± 0.66 6.84 ± 0.52 6.40 ± 0.41 0.62
Low calcium 3.79 ± 0.22 4.17 ± 0.43 3.71 ± 0.33 3.50 ± 0.36 0.45
P (Fc versus Lc) <0.001 <0.001 <0.001 <0.001
Calcium (mmol/2 h) Fasting 0.23 ± 0.02 0.29 ± 0.04 0.21 ± 0.02 0.20 ± 0.03 0.12
Calcium (mmol/4 h) 1 g oral calcium
load
0.97 ± 0.04 1.15 ± 0.09 0.96 ± 0.10 0.80 ± 0.08 0.04∗
Phosphate (mmol/day) (10.90–32.30) Free-choice 30.3 ± 1.0 30.1 ± 1.9 30.2 ± 1.7 30.6 ± 1.9 0.98
Low calcium 24.4 ± 1.0 24.9 ± 2.1 23.4 ± 1.4 25.3 ± 1.9 0.72
P (Fc versus Lc) <0.001 <0.001 <0.001 <0.001
Magnesium (mmol/day) (<12.0) Free-choice 4.54 ± 0.16 4.63 ± 0.27 4.38 ± 0.24 4.65 ± 0.31 0.72
Low-calcium 3.90 ± 0.15 3.87 ± 0.28 3.90 ± 0.22 3.92 ± 0.28 0.99
P (Fc versus Lc) 0.003 0.001 0.02 0.006
Uric acid (µmol/day) (<4760) Free-choice 3191 ± 99 3170 ± 157 3243 ± 162 3146 ± 204 0.92
Low calcium 3146 ± 111 3202 ± 206 3181 ± 184 3042 ± 192 0.83
P (Fc versus Lc) 0.32 0.71 0.39 0.17
The numbers in parentheses indicate the normal range of values.
∗Post hoc analysis P < 0.05, group 1 versus group 3.
Fig. 3. Differential effect of a low-calcium diet on PTH and 1.25 vitamin
D according to bone mineral density at lumbar spine. Groups are indicated
by numbers: 1 = group 1, z-score at lumbar spine <−0.5; 2 = group 2,
z-score at lumbar spine −0.5–0.5; 3 = group 3, z-score at lumbar spine
>0.5. ANOVA P = 0.03 for the 1.25 vitamin D-to-PTH ratios under low-
calcium diet, post hoc analysis P < 0.05 for groups 1 versus 3. Error bars
indicate SEM.
There was a significant association among low BMD
and the percentage of hypercalciuric patients (Figure 4)
with 47% hypercalciuric patients in group 1, 22% in group
2 and 18% in group 3 (chi-square P= 0.03). An analysis of
themineral metabolism in themale participants of the study
yielded results comparable with those of the entire study
population (results not shown). The z-score at the lumbar
spine of all hypercalciuric patients (n = 27) was −0.34
± 0.15, and the corresponding value of all normocalciuric
patients (n=67) 0.20±0.12 (P=0.01) (Table 4). Similarly,
the z-scores at the femoral neck and the tibial dia- and
epiphysis were higher in normo- than in the hypercalciuric
patients (Table 4).
Fig. 4. Hypercalciuric patients and bone mineral density at lumbar spine.
Group 1: z-score <−0.5, n = 30; group 2: z-score −0.5–0.5, n = 36;
group 3: z-score >0.5, n = 28. Numbers in the bars indicate the number
of normocalciuric (blank areas) or hypercalciuric (hatched areas) patients
in the respective groups.
Figure 5 shows calciuria, expressed as calci-
uria/creatinine in mmol/mmol for direct comparison of
24-h, 2-h and 4-h urines, while on the different diets. Calci-
uria declined from group 1– to 3 on all four dietary condi-
tions (ANOVA P = 0.009, post hoc analysis significant for
group 1 versus 3 at P < 0.01), an effect numerically most
pronounced after the 1 g calcium load. When all patients
were considered and grouped into normo- and hypercalci-
uric patients, the switch from a free-choice diet to a low-
calcium diet caused similar changes of PTH and 1.25 vita-
min D in patients with low BMD (Figure 6A), whereas a
differential effect was observed for patients with a normal
or high BMD (Figure 6B).
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Table 4. DEXA z-scores of hypercalciuric and normocalciuric patients
Patients Lumbar
spine
Femoral
neck
Tibial
diaphysis
Tibial
epiphysis
Hypercalciuric, n = 27 −0.34 ±
0.15
0.08 ±
0.13
0.34 ±
0.26
−0.64 ±
0.20
Normocalciuric, n = 67 0.20 ±
0.12
0.36 ±
0.13
0.54 ±
0.12
−0.15 ±
0.11
P∗ 0.01 0.21 0.44 0.03
∗P-value of hypercalciuric versus normocalciuric patients (t-test for un-
paired observations).
Fig. 5. Impact of different regimens on urinary calcium excretion in sub-
jects grouped according to bone mineral density at lumbar spine. Calcium
excretion and creatinine were measured in 24-h urines under free-choice
diet and low-calcium diet, in 2-h urines after 12-h fasting, and in 4-h-
urines after a 1-g calcium load. Data are expressed as calcium/creatinine,
mmol/mmol. Group 1: z-score<−0.5, n= 30; group 2: z-score−0.5–0.5,
n = 36; group 3: z-score >0.5, n = 28. Error bars indicate SEM.
Discussion
In the present study a cohort of 94 unselected renal cal-
cium stone formers was investigated on a free-choice diet,
followed by a low-calcium diet for 1 week and a 1 g oral
calcium load test after 12 h of fasting (Figure 1). When
all patients were considered as one group, dietary calcium
restriction caused a slight but significant decline in plasma
calcium concentration associated with an increase in PTH
and 1.25 vitamin D levels and a substantial reduction of
calciuria (Figure 2). Thus, the anticipated physiologic re-
sponse to the low-calcium diet was observed, suggesting a
high degree of compliance of our patients to the diet.
In previous studies investigating the relationship between
calcium stone formers and reduced BMD, patients were
classified according to the amount of urinary calcium ex-
cretion, followed by an analysis of the corresponding BMD
[2–5,17]. The focus of our investigation was different. We
first grouped the calcium stone formers into three tertiles
according to their lumbar BMD and then analysed the min-
eral metabolism on free-choice and low calcium diet as a
function of BMD. To avoid a bias caused by the distribution
of z-scores, which represent a standard deviation score, pa-
tients were grouped into cohorts representing one standard
deviation each (z-score group 1: <−0.5, group 2: −0.5–
0.5 and group 3: >0.5). Interestingly, when the patients
were grouped according to their BMD, a differential BMD-
dependent response of PTH and 1.25 vitamin D to the low
calcium diet was observed.
Urinary calcium excretion increased with declining
BMD (Figure 5). This phenomenon is not explained by
a differential nutritional behaviour during the study peri-
ods, because it was also present while fasting and after
the standardized 1-g calcium load. The percentage of sub-
jects with hypercalciuria (fasting or absorptive) according
to the definition provided on the basis of previous stud-
ies [2,4,8,12,14] declined in our study from 47% in pa-
tients with the lowest mineral bone density to 18% in pa-
tients with the highest density. This finding is in line with
the reported predictive value of calciuria on bone loss in
stone formers [18]. In line with previous reports [2–4,7,8],
BMD was diminished in hypercalciuric when compared to
normocalciuric patients (Table 4). For most hypercalciuric
patients reported in the literature so far, the underlying
hypercalciuria-causing mechanism is unknown and the
search for monogenic diseases was mostly unsuccessful
[19]. One reason for the absence of success might be the
difficulty to define unambiguous phenotypes. In this re-
gard, challenging dietary conditions, as the ones used in
Fig. 6. Mineral metabolism in hypercalciuric and normocalciuric patients with low (A) and normal/high (B) bone mineral density. Arrows indicate the
changes in mineral metabolism when patients were switched from free-choice to low-calcium diet. Low bone mineral density: DEXA z-score at lumbar
spine <−0.5; normal/high bone mineral density: DEXA z-score at lumbar spine >−0.5. Error bars indicate SEM.
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the present study, might ultimately help to define discrete
entities. For clinical practice, the observation that hypercal-
ciuric patients are at risk to lose bone mass is relevant and
supports the treatment of hypercalciuric stone formers with
a thiazide diuretic. This group of diuretics enhances renal
calcium reabsorption, preserves BMD [20,21] and reduces
the risk of bone fractures [22].
The finding of a link between BMD in calcium stone
formers and the responses of 1.25 vitamin D and PTH to a
low-calcium diet has not been described before (Figure 3).
Starting from a homogenous baseline on free-choice diet
(Figure 3), 1.25 vitamin D and PTH levels differentially
increased on the low-calcium diet: in group 1, the group of
patients with the lowest z-scores, the increase of 1.25 vita-
min D was most pronounced, whereas for PTH the largest
increase was found in group 3, the patients with the highest
z-scores (Figure 3). The putativemechanisms explaining the
BMD-related differential regulation of mineral metabolism
(Figure 3) were not addressed by this study and are still
speculative. Some of them are discussed hereafter.
(a) High phosphate concentrations stimulate PTH release
[23] and inhibit the 1α-hydroxylase [24], thus regulat-
ing PTH and 1.25 vitaminD concentrations. Since both
plasma and urinary phosphate concentrations were of
the same magnitude in the three groups, phosphate
is unlikely to explain the BMD-dependent apparent
low-calcium diet induced regulation of PTH and 1α-
hydroxylase.
(b) Hypocalcaemia stimulates both the excretion of PTH
[25] and the activity of the 1α-hydroxylase [26]. How-
ever, the small changes observed in calcium concen-
trations are similar in all three groups and therefore
might not account for a differential regulation. Never-
theless it is conceivable that the concentration response
curve between calcium and PTH or calcium and 1α-
hydroxylase might be different in the three groups.
(c) Since PTH is a powerful stimulus of the 1α-
hydroxylase [27,28], one might interpret the present
finding as a PTH resistance in group 3 or a hypersensi-
tivity in group 1. The 1α-hydroxylase response to PTH
is blunted in acidosis [29]. However, the absence of sig-
nificant differences of plasma pH, plasma bicarbonate
and urinary citrate levels between the three groups ar-
gues against this possibility. Furthermore, given the
same amount of urinary excretion of urea and sulfate
in all three groups of patients investigated, it is unlikely
that different amounts of proteins, the main nutritional
source of protons, were consumed.
(d) The renal 1α-hydroxylase decreases whereas PTH lev-
els increase with decreasing renal function [30]. The
non-significant differences of plasma creatinine and
creatinine clearance are however unlikely to explain
this differential response.
(e) The biologically active free serum concentration of
1.25 vitamin D is very low as 1.25 vitamin D is
>99% bound to vitamin D binding protein and al-
bumin [31]. In the present study as in all other inves-
tigations in the field, only the total concentrations of
this steroid were assessed. Thus the observed differ-
ences might not be biologically relevant, a contention
unlikely to be true because severe dysproteinemias
have to be present for changing protein binding of
vitamin D [32]. In conclusion, none of the five mecha-
nismsmentioned is likely to account for the differential
changes of PTH and 1.25 vitamin D after a low calcium
diet.
Although the observation of a differential regulation of
PTH and 1.25 vitamin D on a low calcium diet currently
remains unexplained, the resulting PTH and 1.25 vitamin
D levels at the end of the low calcium diet might explain
the results from the 1 g calcium load. In the group with the
highest 1.25 vitamin D levels (group 1), urinary calcium
excretion was highest, and in the group with the lowest
1.25 vitamin D levels (group 3), calcium excretion was the
lowest, suggesting an intact intestinal response for 1.25 vi-
tamin D. The higher PTH concentrations in group 3, com-
pared to group 1, might in addition favour renal calcium
retention. The observation of relatively high 1.25 vitamin
D concentrations in the absence of concomitantly increased
PTH levels in group 1 with a low BMD is reminiscent of
adynamic bone disease as it is encountered in patients with
renal failure. These patients are characterized by a very low
capacity to buffer calcium and to handle an extra calcium
load [33]. Thus it is reasonable to speculate that our patients
with lowBMD following time periods with low-calcium in-
take exhibit normal or even exaggerated intestinal calcium
absorption, but cannot deposit this extra amount of cal-
cium into their bones. As a corollary, calciuria increases.
If this reasoning was correct, then the primary defect caus-
ing the association of low BMD and renal calcium stone
formation might be attributable to a primary bone prob-
lem, with a diminished capacity to utilize the absorbed
calcium.
In conclusion, our study on calcium stone formers pro-
vides an observation on how they adapt to a low-calcium
diet and shows a link between lumbar spine BMD and
calciuria. Whether this association is a peculiar feature of
stone-forming patients or also applies to non-stone formers
cannot be answered by our study at the present time because
of the absence of a cohort of non-stone formers analysed
with the same protocol.
The observed differential response of PTH and 1.25 vi-
tamin D after a 1-week challenge by a low calcium diet
between calcium stone formers with high and low BMD
appears teleologically to be sound: the primary regula-
tor of intestinal calcium absorption, 1.25 vitamin D, is
increased in patients with low BMD, whereas the princi-
pal activator of osteoclasts, PTH, is increased in patients
with high BMD. These findings deserve further investi-
gations in order to elucidate the mechanisms by which
they appear, but are of high relevance by underscoring
the relationship between low mineral bone density and
hypercalciuria.
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